Eva MD - IO Biotech Chief Officer

IOBT Stock  USD 0.92  0.04  4.55%   

Insider

Eva MD is Chief Officer of IO Biotech
Age 60
Phone45 70 70 29 80
Webhttps://www.iobiotech.com

IO Biotech Management Efficiency

The company has return on total asset (ROA) of (0.4591) % which means that it has lost $0.4591 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.785) %, meaning that it created substantial loss on money invested by shareholders. IO Biotech's management efficiency ratios could be used to measure how well IO Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
IO Biotech currently holds 2.49 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. IO Biotech has a current ratio of 20.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about IO Biotech's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Lina GuguchevaNewAmsterdam Pharma
37
John CastleMonte Rosa Therapeutics
54
Sharon TownsonMonte Rosa Therapeutics
50
Abhinav ShuklaShattuck Labs
52
Eric RojasStoke Therapeutics
N/A
Caroline GodfreyPepGen
N/A
Jason CPAMediciNova
47
Gregory RussottiCentury Therapeutics
58
Frederic CrenInventiva Sa
59
FACC FaccNewAmsterdam Pharma
65
Erin JDShattuck Labs
44
Ellen MBAWerewolf Therapeutics
48
Owen WallaceMonte Rosa Therapeutics
55
Filip MDMonte Rosa Therapeutics
51
Sean JeffriesDesign Therapeutics
45
Phil JDMonte Rosa Therapeutics
45
Peng MDPharvaris BV
47
Irena KonstantinovaInventiva Sa
N/A
Sonia DPHILPepGen
38
David MDErasca Inc
41
Michael CooremanInventiva Sa
67
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Io Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. IO Biotech (IOBT) is traded on NASDAQ Exchange in USA. It is located in Ole MaalOees Vej 3, Copenhagen, Denmark, 2200 and employs 78 people. IO Biotech is listed under Biotechnology category by Fama And French industry classification.

Management Performance

IO Biotech Leadership Team

Elected by the shareholders, the IO Biotech's board of directors comprises two types of representatives: IO Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IOBT. The board's role is to monitor IO Biotech's management team and ensure that shareholders' interests are well served. IO Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IO Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
MaiBritt Zocca, President, Founder
Qasim MD, Chief Officer
Faical Miyara, Chief Officer
Brian CPA, Chief Officer
Amy Sullivan, Chief Officer
Anders Ljungqvist, Founder
Brian Burkavage, Chief Officer
Pr Andersen, Founder Advisor
Eva MD, Chief Officer
Pr MD, CoFounder Advisor
Pr Straten, Founder
Devin Smith, General Secretary
Daniel Mannix, Senior Affairs
Eric MBA, Chief Officer
Muhammad AlHajj, Chief Officer
Mikkel Dybkjr, VP Fin
Amy MBA, Chief Officer
Devin JD, General Secretary
Marjan PharmD, Senior Lead
Diane McDowell, Senior Affairs

IOBT Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IO Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for IOBT Stock Analysis

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.